Saturday, June 13, 2026

Latest

Starbucks: Analysts Expect Q1 Revenues Of $7.95 Billion

Starbucks (NASDAQ: SBUX) will be reporting its first quarter financial results on February 1st before the market opens. Analysts have a consensus $121.97 12-month price target on the company, via a total of 37 analysts, with 9 analysts having strong buy ratings.

Nine analysts meanwhile have buy ratings, 18 analysts have a hold rating and a single analyst has a strong sell rating on the company. The street high comes from Kalinowski Equity Research with a $148 price target, and the lowest target sits at $96.

26 analysts have revenue estimates for the first quarter. The mean revenue estimate between all 26 analysts is $7.95 billion; this number has been flat since October 30th. The highest revenue estimate is $8.18 billion, while the lowest is $7.4 billion.

Onto EBITDA estimates, there are currently 18 analysts who have first-quarter EBITDA estimates. The mean is currently $1.66 billion, with this number having been revised downwards from $1.71 billion at the end of October. The street high estimate currently sits at $1.82 billion in EBITDA and the lowest is $1.49 billion.

Analysts estimate that quarterly earnings per share will come in at $0.80, with this number flat since the end of October. The street high sits at $0.90 and the lowest estimate is $0.72 per share for the quarter.


Information for this briefing was found via Sedar and Refinitiv. The author has no securities or affiliations related to this organization. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.

Video Articles

The Canadian Dream Is Leaving Canada | Spencer Gatten

Allied Gold: The Zijin Deal Is On The Rocks

Why Silver’s Drop May Not Mean the Bull Market Is Over | Peter Krauth

Recommended

Silver47 Starts 10,000 Metre Campaign at Flagship Alaska Silver Project

Blue Jay Gold Launches 16,000 Metre Drill Program At Steller

Related News

Antibe: Canaccord Cuts Price Target From $5.00 To $1.20 After Drug Pivot

In early August, Antibe Therapeutics Inc. (TSX: ATE) announced that they have paused their study...

Monday, October 18, 2021, 11:31:00 AM

Green Thumb: Analysts Upgrade Ratings On Back Of Earnings Beat

This morning Canaccord Genuity raised their 12-month price target on Green Thumb Industries (CSE: GTII)...

Thursday, November 12, 2020, 10:50:37 AM

PLBY Group: Canaccord Nearly Doubles Price Target

PLBY Group (NASDAQ: PLBY) reported their first quarter financial results earlier this week. The company...

Friday, May 14, 2021, 06:12:00 PM

Tilray Sees Haywood Slash Price Target To $12.50

On October 7, Tilray Inc (TSX: TLRY) reported their first quarter financial results for the...

Sunday, October 10, 2021, 04:49:00 PM

Canaccord Reiterates Ratings On Uranium Royalty Following Latest Purchase

On December 2nd, Uranium Royalty Corp (TSXV: URC) announced that they have entered into a...

Sunday, December 5, 2021, 12:56:00 PM